ALPMY - Astellas Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
12.925
-0.095 (-0.730%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close13.020
Open0.000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume81,231
Market Cap26.82B
Beta0.39
PE Ratio (TTM)15.24
EPS (TTM)0.848
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2016-09-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube4 days ago

    ETFs with exposure to Astellas Pharma, Inc. : November 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Reuters5 days ago

    Astellas faces U.S. probe over patient assistance charity support

    Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. In a lawsuit filed on Monday in federal court in Chicago against its insurers, a unit of Japan's Astellas, said the U.S. Justice Department was conducting a joint criminal and civil investigation of the company, its officers and its employees. Astellas US Holdings Inc said it first received a subpoena from the Justice Department in March 2016 in connection with the industry-wide probe and on Oct. 26 entered into an agreement that essentially allows for an extension of the statute of limitations.

  • Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q2, 2018 By the Numbers : November 15, 2017
    Capital Cube5 days ago

    Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q2, 2018 By the Numbers : November 15, 2017

    Categories: Yahoo FinanceGet free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Astellas Pharma, Inc. – Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Amgen Inc. and Vical Incorporated (JNJ-US, PFE-US, MRK-US, AMGN-US and VICL-US) that have also reported ... Read more (Read more...)

  • PR Newswire12 days ago

    Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer

    TOKYO and BOTHELL, Wash., Nov. 8, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"), and Seattle Genetics, Inc. (SGEN) today announced dosing of the first patient in EV-103, a phase 1b clinical trial evaluating the safety and tolerability of enfortumab vedotin in combination with pembrolizumab or atezolizumab, two types of immune checkpoint inhibitor (CPI) therapies, for first- or second-line treatment of patients with locally advanced or metastatic urothelial cancer. Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) designed to deliver the cell-killing agent monomethyl auristatin E (MMAE) to the target Nectin-4. "The initiation of EV-103 is an important step in investigating the utility of enfortumab vedotin in earlier lines of therapy, including the first-line setting, for locally advanced and metastatic urothelial cancer, where patients ineligible for cisplatin-based chemotherapy continue to have limited treatment options," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics.

  • Capital Cube18 days ago

    ETFs with exposure to Astellas Pharma, Inc. : November 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 30th, 2017 (record date) : By the numbers : October 23, 2017
    Capital Cube28 days ago

    Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 30th, 2017 (record date) : By the numbers : October 23, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Astellas Pharma, Inc. with the following peers – Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Amgen Inc. and Vical Incorporated (JNJ-US, PFE-US, MRK-US, AMGN-US and VICL-US). Astellas Pharma, Inc.’s dividend yield is 1.87 percent and its dividend payout is percent. This compares to ... Read more (Read more...)

  • Cancer Space Update: Lung & Breast Cancer Studies in Focus
    Zackslast month

    Cancer Space Update: Lung & Breast Cancer Studies in Focus

    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

  • PR Newswirelast month

    U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia

    TOKYO, Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of gilteritinib for adult patients with FLT3 mutation-positive (FLT3+) relapsed or refractory acute myeloid leukemia (AML). Fast Track designation is designed to facilitate the development, and expedite the FDA review, of drugs to treat serious and life-threatening conditions so that, if approved, the compounds can reach the market expeditiously.

  • PR Newswirelast month

    Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

    TOKYO and BOTHELL, Wash., Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics Inc., (SGEN) today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor (CPI) therapy. The EV-201 study will assess the antitumor activity and safety of enfortumab vedotin to support potential registration under the U.S. Food and Drug Administration's (FDA) accelerated approval regulations. In addition, there are no FDA-approved therapies for patients who progress following CPI treatment," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics.

  • Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 30th, 2017 (record date) : By the numbers : October 6, 2017
    Capital Cubelast month

    Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 30th, 2017 (record date) : By the numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Astellas Pharma, Inc. with the following peers – Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Amgen Inc. and Vical Incorporated (JNJ-US, PFE-US, MRK-US, AMGN-US and VICL-US). Astellas Pharma, Inc.’s dividend yield is 0.85 percent and its dividend payout is percent. This compares to ... Read more (Read more...)

  • Why Did Pfizer (PFE) Stock Pop Today?
    Zacks2 months ago

    Why Did Pfizer (PFE) Stock Pop Today?

    Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.

  • Reuters2 months ago

    Pfizer, Astellas prostate cancer drug promising in late-stage trial

    Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages. The positive data sets the stage for an earlier-than-expected approval of the drug, which is already cleared to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body.

  • Reuters2 months ago

    UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial

    Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease. The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body - and raked in U.S. sales of $141 million in the second quarter for Pfizer.

  • PR Newswire2 months ago

    Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

    - Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical ...

  • PR Newswire2 months ago

    U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

    TOKYO, Sept. 12, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) that seeks approval for the use of mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The anticipated Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is April 28, 2018.

  • Capital Cube3 months ago

    ETFs with exposure to Astellas Pharma, Inc. : August 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire3 months ago

    First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia

    TOKYO, Aug. 21, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the first patient was dosed in the registrational Phase 3 MORPHO trial of gilteritinib, the fourth Phase 3 trial underway in the gilteritinib clinical development program. The MORPHO trial is a randomized, double-blind, placebo-controlled, multi-center trial that compares gilteritinib to placebo as maintenance therapy over a period of two years following hematopoietic stem cell transplant (HCT) in patients with FLT3 internal tandem duplication (ITD) mutation-positive (FLT3/ITD+) acute myeloid leukemia (AML) and in remission after induction therapy.

  • Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q1, 2018 By the Numbers : August 21, 2017
    Capital Cube3 months ago

    Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q1, 2018 By the Numbers : August 21, 2017

    Categories: Yahoo FinanceGet free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Astellas Pharma, Inc. – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc. and Vical Incorporated (JNJ-US, MRK-US, PFE-US, AMGN-US and VICL-US) that have also reported ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Astellas Pharma, Inc. : August 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire4 months ago

    Astellas Announces Wind-Down of Agensys Research Operations

    TOKYO, July 26, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that it is winding down its Agensys research operations in Santa Monica, California, USA, to further refine its oncology strategy by expanding its investment in the research in new technologies and modalities and reducing its focus on Antibody-Drug Conjugate (ADC) research. "Agensys has positively contributed to Astellas' objective of developing innovative treatments for patients with cancer," said Wataru Uchida, Ph.D., senior vice president, Drug Discovery Research (DDR), Astellas.

  • PR Newswire4 months ago

    U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia

    TOKYO, July 20, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation to gilteritinib in patients with acute myeloid leukemia (AML). "Fewer than 10,000 Americans will be diagnosed with FLT3 mutation-positive AML this year and while that may be a small percentage of the overall population, it is an important group of patients who are deserving of potential new treatments," said Steven Benner, M.D., senior vice president and global therapeutic area head, oncology development, Astellas.

  • Capital Cube4 months ago

    ETFs with exposure to Astellas Pharma, Inc. : July 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire5 months ago

    Astellas Submits Supplemental New Drug Application for Mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

    TOKYO, June 29, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. In the United States, mirabegron and solifenacin succinate are marketed as Myrbetriq® and VESIcare®, respectively.

  • Capital Cube5 months ago

    ETFs with exposure to Astellas Pharma, Inc. : June 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)